Abstract LB460: Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models

Abstract Microsatellite instability, caused by defects in DNA mismatch repair, is a feature of many cancers including colorectal, gastric, endometrial, and ovarian. Werner helicase (WRN), a RecQ helicase involved in genome maintenance and DNA damage repair, is essential for cancer cells with high microsatellite instability (MSI-H), making it a promising target for the treatment of MSI-H cancers. Here we characterize a new non-covalent WRN inhibitor, ARTS-051, which is potent and selective across multiple MSI-H colorectal cancer models. In enzymatic assays, ARTS-051 inhibits WRN ATPase and helicase activity and displays over 2000-fold selectivity for WRN over the most closely related RecQ helicase, BLM. ARTS-051 also demonstrates excellent potency against the proliferation of both highly sensitive MSI-H cell lines (HCT116 and SW48) and less sensitive MSI-H cell lines (SNU-407 and RKO). At the same time, ARTS-051 exhibits more than 90-fold selectivity over microsatellite stable (MSS) cell line HT29. Mutation of WRN C727 confers resistance to existing WRN inhibitors, making it a potential vulnerability of these inhibitors. In contrast, ARTS-051 is effective in WRN C727S and C727A mutant HCT116 cells, outperforming the clinical stage WRN inhibitor HRO761 by nearly 10-fold. In multiple MSI-H cell-line derived mouse models including the less sensitive RKO and mutant WRN C727S HCT116 models, treatment with ARTS-051 leads to tumor regression without significant toxicity. Additionally, ARTS-051 displays good drug-like properties including solubility, permeability, and liver microsome stability, as well as a positive PK profile with low clearance and good oral exposure across species, supporting favorable clinical dose projections. Taken together, these data show that ARTS-051 is a promising WRN inhibitor with best-in-class potential to treat MSI-H colorectal cancers. Citation Format: Christine Moomau, Jiaqi Liang, Jian Lin, Xiaozhi Yang, Wenheng Liang, John Campbell, Yipin Lu, David Pirovich, Tao Ji, Lina Gu, Fang Li, Yaoyu Chen, Xiang Zhai. Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB460.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-17
DOI
https://doi.org/10.1158/1538-7445.am2026-lb460
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract LB460: Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models

Xiaozhi Taro Yang, Yaoyu Chen, Xiang Zhai, David B. Pirovich et al.
Cancer Research
PARP inhibition in cancer therapy
article

Abstract LB460: Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models

Xiaozhi Taro Yang, Yaoyu Chen, Xiang Zhai, David B. Pirovich, Yipin Lu, Tao Ji, Lina Gu, Wenheng Liang, Fang Li, Christine Moomau, Jiaqi Liang, John Campbell, Jian Lin
article en

Abstract

Abstract Microsatellite instability, caused by defects in DNA mismatch repair, is a feature of many cancers including colorectal, gastric, endometrial, and ovarian. Werner helicase (WRN), a RecQ helicase involved in genome maintenance and DNA damage repair, is essential for cancer cells with high microsatellite instability (MSI-H), making it a promising target for the treatment of MSI-H cancers. Here we characterize a new non-covalent WRN inhibitor, ARTS-051, which is potent and selective across multiple MSI-H colorectal cancer models. In enzymatic assays, ARTS-051 inhibits WRN ATPase and helicase activity and displays over 2000-fold selectivity for WRN over the most closely related RecQ helicase, BLM. ARTS-051 also demonstrates excellent potency against the proliferation of both highly sensitive MSI-H cell lines (HCT116 and SW48) and less sensitive MSI-H cell lines (SNU-407 and RKO). At the same time, ARTS-051 exhibits more than 90-fold selectivity over microsatellite stable (MSS) cell line HT29. Mutation of WRN C727 confers resistance to existing WRN inhibitors, making it a potential vulnerability of these inhibitors. In contrast, ARTS-051 is effective in WRN C727S and C727A mutant HCT116 cells, outperforming the clinical stage WRN inhibitor HRO761 by nearly 10-fold. In multiple MSI-H cell-line derived mouse models including the less sensitive RKO and mutant WRN C727S HCT116 models, treatment with ARTS-051 leads to tumor regression without significant toxicity. Additionally, ARTS-051 displays good drug-like properties including solubility, permeability, and liver microsome stability, as well as a positive PK profile with low clearance and good oral exposure across species, supporting favorable clinical dose projections. Taken together, these data show that ARTS-051 is a promising WRN inhibitor with best-in-class potential to treat MSI-H colorectal cancers. Citation Format: Christine Moomau, Jiaqi Liang, Jian Lin, Xiaozhi Yang, Wenheng Liang, John Campbell, Yipin Lu, David Pirovich, Tao Ji, Lina Gu, Fang Li, Yaoyu Chen, Xiang Zhai. Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB460.

Cancer ResearchVol. 86(8_Supplement)
Bioscience (China) (CN), Cytori Therapeutics (United States) (US)
Openalex Percentile: Top 21%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.